ZA202300378B - Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences - Google Patents
Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequencesInfo
- Publication number
- ZA202300378B ZA202300378B ZA2023/00378A ZA202300378A ZA202300378B ZA 202300378 B ZA202300378 B ZA 202300378B ZA 2023/00378 A ZA2023/00378 A ZA 2023/00378A ZA 202300378 A ZA202300378 A ZA 202300378A ZA 202300378 B ZA202300378 B ZA 202300378B
- Authority
- ZA
- South Africa
- Prior art keywords
- nucleic acid
- acid constructs
- mecp2
- binding protein
- promoter sequences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064431P | 2020-08-12 | 2020-08-12 | |
| PCT/EP2021/072365 WO2022034130A1 (en) | 2020-08-12 | 2021-08-11 | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202300378B true ZA202300378B (en) | 2024-04-24 |
Family
ID=77655525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/00378A ZA202300378B (en) | 2020-08-12 | 2023-01-09 | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022131322A1 (cg-RX-API-DMAC7.html) * | 2020-12-17 | 2022-06-23 | ||
| IL312340A (en) * | 2021-10-28 | 2024-06-01 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
| WO2024163823A1 (en) * | 2023-02-02 | 2024-08-08 | Shape Therapeutics Inc. | Tissue-specific enhancers for regulating transcription |
| JP2026509301A (ja) * | 2023-03-14 | 2026-03-17 | ユーシービー バイオファルマ エスアールエル | 遺伝子治療 |
| CN121335978A (zh) * | 2023-06-16 | 2026-01-13 | 舒泰神(北京)生物制药股份有限公司 | 一种人源MeCp2启动子及其用途 |
| WO2025213097A1 (en) * | 2024-04-05 | 2025-10-09 | The Children's Hospital Of Philadelphia | Novel gene therapy constructs for stxbp1 haploinsufficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110045536A1 (en) * | 2007-12-21 | 2011-02-24 | Novartis Ag | Mammalian expression vector |
| CN104583402A (zh) * | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| CN114717264A (zh) * | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| AU2015349759B2 (en) * | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| JP6754361B2 (ja) * | 2014-12-16 | 2020-09-09 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| CA3016314A1 (en) * | 2016-03-02 | 2017-09-08 | Julianne REIDERS | Therapy for frontotemporal dementia |
| TWI601821B (zh) * | 2016-04-15 | 2017-10-11 | 中央研究院 | 治療神經發展性疾病 |
| WO2020081490A1 (en) * | 2018-10-15 | 2020-04-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
-
2021
- 2021-08-11 MX MX2023001701A patent/MX2023001701A/es unknown
- 2021-08-11 AR ARP210102238A patent/AR123206A1/es unknown
- 2021-08-11 AU AU2021325717A patent/AU2021325717A1/en active Pending
- 2021-08-11 PH PH1/2023/550145A patent/PH12023550145A1/en unknown
- 2021-08-11 BR BR112023002374A patent/BR112023002374A2/pt unknown
- 2021-08-11 US US18/021,005 patent/US20230295657A1/en active Pending
- 2021-08-11 CA CA3188748A patent/CA3188748A1/en active Pending
- 2021-08-11 TW TW110129603A patent/TWI902867B/zh active
- 2021-08-11 EP EP21766127.1A patent/EP4196171A1/en active Pending
- 2021-08-11 PE PE2023000142A patent/PE20230914A1/es unknown
- 2021-08-11 CN CN202180056525.5A patent/CN116113441B/zh active Active
- 2021-08-11 WO PCT/EP2021/072365 patent/WO2022034130A1/en not_active Ceased
- 2021-08-11 JP JP2023509770A patent/JP7860958B2/ja active Active
- 2021-08-11 KR KR1020237007287A patent/KR20230044506A/ko active Pending
- 2021-08-11 IL IL300294A patent/IL300294A/en unknown
-
2023
- 2023-01-09 ZA ZA2023/00378A patent/ZA202300378B/en unknown
- 2023-01-16 CO CONC2023/0000444A patent/CO2023000444A2/es unknown
- 2023-02-10 CL CL2023000419A patent/CL2023000419A1/es unknown
- 2023-03-08 EC ECSENADI202316688A patent/ECSP23016688A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023000444A2 (es) | 2023-01-26 |
| EP4196171A1 (en) | 2023-06-21 |
| IL300294A (en) | 2023-04-01 |
| JP7860958B2 (ja) | 2026-05-18 |
| AU2021325717A1 (en) | 2023-03-02 |
| CL2023000419A1 (es) | 2023-07-21 |
| CA3188748A1 (en) | 2022-02-17 |
| PE20230914A1 (es) | 2023-06-02 |
| TW202221018A (zh) | 2022-06-01 |
| US20230295657A1 (en) | 2023-09-21 |
| WO2022034130A1 (en) | 2022-02-17 |
| CN116113441A (zh) | 2023-05-12 |
| PH12023550145A1 (en) | 2024-03-18 |
| KR20230044506A (ko) | 2023-04-04 |
| BR112023002374A2 (pt) | 2023-03-21 |
| CN116113441B (zh) | 2026-06-09 |
| AR123206A1 (es) | 2022-11-09 |
| JP2023537980A (ja) | 2023-09-06 |
| TWI902867B (zh) | 2025-11-01 |
| ECSP23016688A (es) | 2023-04-28 |
| MX2023001701A (es) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550145A1 (en) | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| WO2022256500A3 (en) | Dll3 targeting trispecific proteins and methods of use | |
| WO2022256498A9 (en) | Msln targeting trispecific proteins and methods of use | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
| ZA202104912B (en) | Rna encoding a protein | |
| NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
| US20230242627A1 (en) | Composition and method for activating latent human immunodeficiency virus (hiv) | |
| WO2021130537A3 (en) | Compositions and methods for simultaneously modulating expression of genes | |
| CA2197286A1 (en) | Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs | |
| MX2023012509A (es) | Vectores aavrh74 para la terapia génica de distrofias musculares. | |
| WO2014016580A1 (en) | Transgene expression | |
| ATE475713T1 (de) | Trans-lentivirales vektor system | |
| CO2022014515A2 (es) | Itr libres de cpg para terapia génica aav | |
| JOP20250158A1 (ar) | بروتين ثلاثى النوع يستهدف trop2 لعلاج السرطان | |
| ZA202310639B (en) | Interleukin 15 variants | |
| ATE285239T1 (de) | Dna enthaltende impfstoffen | |
| WO2023010120A3 (en) | Engineering aav vectors with improved cns targeting | |
| MX2023013078A (es) | Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos. | |
| EP1149917A3 (en) | Hepatitis B virus vectors for gene therapy | |
| WO2003029433A3 (en) | Chimeric viral vectors for gene therapy | |
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| MX2024003241A (es) | Terapia genica con frataxina. | |
| HK40089962A (en) | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences |